

## Lung Transplantation for Interstitial Lung Disease: evolution over three decades

### Online supplement

**Table 1**

Characteristics	IPF (n=186)	Fibrotic NSIP (n=23)	p-value
Median follow-up (years)	4.0 [1.0-7.2]	1.2 [0.4-3.8]	<b>0.0023</b>
Age at transplantation (years)	56 [49-60]	52 [46-59]	0.2106
Sex, male (n, %)	136 (73.1)	13 (56.5)	0.0970
Waiting time (days)	125 [51-253]	354 [132-586]	<b>0.0024</b>
Type of transplant (n, %)			0.4121
Heart-lung	2 (1.1)	0 (0)	
Single lung	97 (52.2)	9 (39.1%)	
Bilateral lung	87 (46.8)	14 (60.9%)	
Ex-smoker	93 (61.2)	10 (45.5)	0.2004
Treatment at time transplant			<b>0.0051</b>
Prednisolone	91 (61.5)	21 (91.3)	
Comorbidities (n, %)			
Pulmonary hypertension	48 (31.2)	4 (17.4)	0.1760
GERD	34 (21.8)	9 (39.1)	0.0693
Essential hypertension	22 (14.2)	4 (17.4)	0.6853
Diabetes mellitus	19 (13.6)	2 (9.5)	0.6075
Coronary artery disease	10 (6.2)	1 (4.3)	0.7291
BMI (kg/m <sup>2</sup> )	27.2 (4.2)	27.5 (3.7)	0.7333
eGFR (mL/min/1.73m <sup>2</sup> )	91 [75-102]	92 [82-106]	0.4665
6MWT (m)	285 [168-370]	305 [180-340]	0.7149
Post-transplant complications			
Essential hypertension	95 (56.5%)	11 (52.4%)	0.7168
Chronic kidney disease	90 (53.6%)	10 (47.6%)	0.6064
Diabetes mellitus	42 (25.0%)	3 (14.3%)	0.2771
Bronchial stenosis requiring stenting	5 (3.0%)	0 (0)	0.4230
Pseudomonas aeruginosa culture positive within first year	40 (24.8%)	4 (17.4%)	0.4331
CLAD	65 (38.7%)	7 (33.3%)	0.6336
PTLD	4 (2.4%)	1 (4.8%)	0.5215
Skin malignancy	21 (12.5%)	0 (0)	0.0857
Solid organ malignancy	5 (3.0%)	1 (4.0%)	0.6599

**Table 1** Differences in basic characteristics and post-transplant complications between IPF and fibrotic NSIP

BMI: body mass index, CLAD: chronic lung allograft dysfunction, eGFR: estimated glomerulus filtration rate, GERD: gastroesophageal reflux disease, IPF: idiopathic pulmonary fibrosis, NSIP: non-specific interstitial pneumonia, PTLD: post-transplant lymphoproliferative disease.

**Table 2**

Post-transplant complications	n	All (n, %)	1987 to 2000 (n=54) (n, %)	2001 to 2010 (n=97) (n, %)	2011 to 2020 (n=133) (n, %)	p-value	Time after transplant (years)
Essential hypertension	261	137 (52.5)	12 (38.7)	42 (51.2)	83 (56.1)	0.2040	
Chronic kidney disease	261	134 (51.3)	12 (38.7)	40 (48.8)	82 (55.4)	0.5803	
Diabetes mellitus	261	56 (21.5)	3 (9.7)	22 (26.8)	31 (20.9)	0.1367	
Bronchial stenosis requiring stenting	261	10 (3.8)	1 (3.2)	7 (8.5)	2 (1.4) **	<b>0.0244</b>	
Pseudomonas aeruginosa culture positive Within first year	257	63 (24.5)	4 (18.2)	20 (24.1)	39 (25.7)	0.7483	
CLAD CLAD-BOS CLAD-mixed CLAD-RAS	261	98 (37.5)	11 (35.5)	41 (50.0)	46 (31.1) ** 40 (87.0) 5 (10.9) 1 (2.1)	<b>0.0173</b>	2.7 [1.7, 5.3]
PTLD	261	9 (3.4)	1 (3.2)	3 (3.7)	5 (3.4)	0.9912	0.8 [0.3, 3.3]
Skin malignancy	261	27 (10.3)	4 (12.9)	13 (15.9)	10 (6.8)	0.0839	5.7 [1.4, 14.0]
Solid organ malignancy	261	10 (3.8)	1 (3.2)	3 (3.7)	6 (4.1)	0.9717	13.2 [6.5, 19.1]

**Table 2:** Post-lung transplant complications

BOS = bronchiolitis obliterans syndrome, CLAD= chronic lung allograft dysfunction, PTLD = post-transplant lymphoproliferative disorder, RAS = restrictive allograft syndrome. Chronic kidney disease was defined as an eGFR < 60/ml/min/1.73m<sup>2</sup>. Statistics are Chi-squared test for categorical variables with post-hoc analysis with Bonferroni adjustment (\* compared to 2001-2010, \*\* p<0.01).